The originally planned efficacy analysis over 12 weeks was not performed due to limited data at later time points , but there was evidence that telcagepant resulted in a larger reduction from baseline than placebo for mean monthly headache days ( month 1 : 140 mg = -2.9 , 280 mg = -3.1 , placebo = -1.7 ; p < 0.05 ) and migraine/probable migraine days ( month 1 : 140 mg = -2.7 , 280 mg = -3.0 , placebo = -1.6 ; p < 0.05 ) .